Which drug represents the group of anticoagulants inhibiting factors Va and VIIIa?

The only representative discussed is drotrecogin alfa (activated), a recombinant analogue of activated protein C.

What is the mechanism of the anticoagulant action of drotrecogin alfa?

The drug proteolytically inactivates coagulation cofactors factor Va and factor VIIIa, leading to the inhibition of thrombin generation.

How is the fibrinolytic effect of the agent mediated?

The fibrinolytic action is provided by a reduction in the level of plasminogen activator inhibitor type 1 (PAI-1).

Why are these anticoagulants used in septic shock?

The rationale lies in the pathogenesis of sepsis, which is simultaneously accompanied by systemic inflammation and hypercoagulation — processes targeted by the drug.

Home › Pharmacology › Anticoagulants Inhibiting Factors Va and VIIIa

Anticoagulants Inhibiting Factors Va and VIIIa

*Drotrecoginum alfa activatum*

For medical students2 min readUpdated 2026-10-10

This group of anticoagulants is represented by a recombinant analogue of activated protein C. These agents inactivate key coagulation factors and exhibit anti-inflammatory properties.

RepresentativeDrotrecogin alfa (activated)

Targets of actionCoagulation factors Va and VIIIa

EffectsAnticoagulant, fibrinolytic, anti-inflammatory

ComplicationsHemorrhagic reactions

Characteristics and Mechanism of Action

The sole clinical representative of this group is drotrecogin alfa (activated), which is a recombinant analogue of activated protein C.

The anticoagulant effect is achieved through the proteolytic inactivation of blood coagulation cofactors — factor Va and factor VIIIa. Consequently, this blocks the further generation of thrombin.

Additional Pharmacological Properties

In addition to affecting blood coagulation, the agent exhibits other important properties:

Fibrinolytic activity: achieved by reducing the concentration of plasminogen activator inhibitor type 1 (PAI-1), which stimulates fibrinolysis.
Anti-inflammatory action: the drug suppresses the release of TNF-alpha (tumor necrosis factor) from monocytes.

Clinical Application and Risks

The medical application of these agents includes the treatment of septic shock. This therapeutic strategy is justified by the pathogenesis of severe sepsis, which concurrently involves systemic inflammation and pronounced hypercoagulation.

The primary adverse effect associated with the use of this drug is hemorrhagic reactions.

Frequently asked questions

Which drug represents the group of anticoagulants inhibiting factors Va and VIIIa?: The only representative discussed is drotrecogin alfa (activated), a recombinant analogue of activated protein C.
What is the mechanism of the anticoagulant action of drotrecogin alfa?: The drug proteolytically inactivates coagulation cofactors factor Va and factor VIIIa, leading to the inhibition of thrombin generation.
How is the fibrinolytic effect of the agent mediated?: The fibrinolytic action is provided by a reduction in the level of plasminogen activator inhibitor type 1 (PAI-1).
Why are these anticoagulants used in septic shock?: The rationale lies in the pathogenesis of sepsis, which is simultaneously accompanied by systemic inflammation and hypercoagulation — processes targeted by the drug.

Go deeper

Structure and functions of recombinant activated protein C
Molecular mechanisms of factor Va and VIIIa inactivation
Interaction between the coagulation and plasminogen systems (effect on PAI-1)
Role of TNF-alpha and monocytes in the anti-inflammatory response of the drug
Pathophysiological features of septic shock as an indication for therapy
Prevention and management of hemorrhagic complications